US Patent

US9764003 — Use of long-acting GLP-1 peptides

Method of Use · Assigned to Novo Nordisk AS · Expires 2033-06-21 · 7y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of long-acting GLP-1 peptides in certain dosage regimes for treating type 2 diabetes and obesity.

USPTO Abstract

The invention relates to use of long-acting GLP-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4418 — Ozempic
U-3161 — Ozempic
U-3161 — Ozempic
U-3161 — Ozempic
U-3161 — Ozempic
U-3161 — Ozempic

Patent Metadata

Patent number
US9764003
Jurisdiction
US
Classification
Method of Use
Expires
2033-06-21
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.